Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 4:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Not listed Not applicable Interventional Accepts healthy volunteers

Talc Outpatient Pleurodesis With Indwelling Catheter

NCT03973957
Conditions
Pleural Effusion, Pleural Diseases, Malignant Pleural Effusion
Interventions
Indwelling pleural catheter placement, Fentanyl Citrate, Talc Slurry, Drainage collection bag
Device · Drug
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Camden, New Jersey
Conditions
Clostridium Difficile Associated Disease
Interventions
Clostridium difficile vaccine, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
12
States / cities
DeLand, Florida • Savannah, Georgia • Stockbridge, Georgia + 9 more
Conditions
Postmenopausal Symptoms
Interventions
G-CSF, Placebo/Saline
Biological · Other
Lead sponsor
MenoGeniX, Inc.
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Conditions
Pain Control
Interventions
Bupivacaine infusion, Saline
Combination Product
Lead sponsor
Ascension Health
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Grand Blanc, Michigan
Completed Not applicable Interventional Results available

Retrospective Independent Safety Review of Closed Irrisept Study

NCT05359666
Conditions
Adverse Events
Interventions
Irrisept, Standard of Care
Device
Lead sponsor
Irrimax Corporation
Industry
Eligibility
Not listed
Enrollment
592 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
17
States / cities
Tucson, Arizona • Los Angeles, California • Denver, Colorado + 14 more
Conditions
Acute Burns
Interventions
Magellan®, Placebo Saline Gel and Usual and Customary Standard of Care
Device · Other
Lead sponsor
Arteriocyte, Inc.
Industry
Eligibility
18 Years to 86 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Sacramento, California • Washington D.C., District of Columbia • Salt Lake City, Utah
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of MET233 in Individuals With Obesity or Overweight

NCT07022977
Conditions
Obesity and Overweight
Interventions
MET233, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cypress, California
Conditions
Nausea, Vomiting, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
Decadron®, Benadryl®, Ativan®, ondansetron hydrochloride
Drug
Lead sponsor
University of South Florida
Other
Eligibility
8 Years to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Fort Myers, Florida • Orlando, Florida • Tampa, Florida + 3 more
Conditions
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
Interventions
Insulin, Placebo (Sterile diluent)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Combination HTNV and PUUV DNA Vaccine

NCT03718130
Conditions
Hantaan Virus Disease, Puumala Virus
Interventions
Hantaan virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intradermal Delivery (ID), Hantaan virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intramuscular Delivery (IM), Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID), Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intramuscular Delivery (IM), Hantaan/Puumala (HTNV/PUUV) virus vaccines - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID), Hantaan/Puumala (HTNV/PUUV virus vaccines - Using the TriGrid Delivery System (TDS) for Intramusular Delivery (IM)
Combination Product
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 49 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Coronary Artery Disease
Interventions
Methylnaltrexone, Placebo, Morphine, Ticagrelor
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Dehydration, Acute Gastroenteritis
Interventions
Standard IV Rehydration Therapy, Oral Rehydration Therapy (ORT)
Other
Lead sponsor
Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Other
Eligibility
6 Months to 18 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Miami, Florida
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Intranasal Capsaicin Treatment for Non-Allergic Irritant Rhinitis

NCT02493257
Conditions
Nonallergic Irritant Rhinitis
Interventions
Capsaicin, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Houston, Texas
Conditions
Muscle Atrophy, ACL Reconstruction, Trauma, Osteoarthritis
Interventions
Testosterone, Placebo
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Recruiting Phase 4 Interventional Accepts healthy volunteers

Intravenous Iron Effects on Performance at High Altitude

NCT06686693
Conditions
Hypoxia
Interventions
Injectafer, Placebo
Drug · Other
Lead sponsor
United States Army Research Institute of Environmental Medicine
Federal
Eligibility
18 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Natick, Massachusetts
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of TT301 on Cytokine Levels Post Endotoxin Challenge

NCT01357421
Conditions
Traumatic Brain Injury
Interventions
TT301, Placebo
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Septic Shock
Interventions
FE 202158 1.25, FE 202158 2.5, FE 202158 3.75, Placebo
Drug · Other
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
6
States / cities
Newark, Delaware • Springfield, Massachusetts • Duluth, Minnesota + 3 more
Recruiting Phase 4 Interventional Accepts healthy volunteers

Ketorolac Effects on Post-operative Pain and Lumbar Fusion

NCT06513208
Conditions
Lumbar Spinal Fusion
Interventions
Ketorolac Tromethamine, Placebo
Drug
Lead sponsor
University of Maryland St. Joseph Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Towson, Maryland
Conditions
Herpes Simplex
Interventions
GSK208141, Havrix (investigational formulation), Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 17 Years · Female only
Enrollment
5,960 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
66
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 54 more
Conditions
Myringotomy
Interventions
Dexmedetomidine
Drug
Lead sponsor
Martin Mueller
Other
Eligibility
1 Year to 10 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Vaccines, Meningococcal Vaccines
Interventions
rLP2086 and Gardasil, rLP2086, Gardasil
Biological
Lead sponsor
Pfizer
Industry
Eligibility
11 Years to 17 Years
Enrollment
2,499 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
87
States / cities
Daphne, Alabama • Chandler, Arizona • Jonesboro, Arkansas + 57 more
Terminated Not applicable Interventional Accepts healthy volunteers

Esophageal Absorption in EoE

NCT02314455
Conditions
Eosinophilic Esophagitis
Interventions
D-xylose
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Myocardial Perfusion Imaging
Interventions
Definity
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Cytoscopic Antibiotic Irrigant to Reduce Postoperative Urinary Tract Infection

NCT03099863
Conditions
Urinary Tract Infections
Interventions
Cystoscopic Fluid containing Neosporin G. U. Irrigant, Cystoscopy, Cystoscopic Fluid/Placebo
Drug · Procedure
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
242 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio